13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001819257
Total reported value
$645.5M
$645.5M
11 檔
38.8%
According to the latest 13F quarterly dataset, Patient Square Capital LP managed an equity portfolio of $645.5M at the end of Q3 2024, spanning 11 distinct U.S. exchange-listed positions.
In Q3 2024, Patient Square Capital LP displayed an active expansion posture, initiating 9 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 52.38% | +3.84% | — | |
| 2 | LQDA | Liquidia CORP | Stock-Other | 26.66% | — | — | |
| 3 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 5.12% | — | — | |
| 4 | INSM | Insmed Inc | Stock-Healthcare | 4.65% | -4.57% | EXIT | |
| 5 | EYPT | Eyepoint Inc | Stock-Other | 4.04% | -0.22% | — | |
| 6 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.72% | — | — | |
| 7 | PHVS | Pharvaris N.V. | Stock-Other | 1.67% | +1.13% | — | |
| 8 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.98% | — | — | |
| 9 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.86% | +0.28% | — | |
| 10 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.76% | — | — | |
| 11 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.16% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CGEM | Cullinan Therapeutics Inc | +5.1% | NEW | New buy |
| 2 | INSM | Insmed Inc | +4.7% | NEW | New buy |
| 3 | EYPT | Eyepoint Inc | +4% | NEW | New buy |
| 4 | NRIX | Nurix Therapeutics Inc | +2.7% | NEW | New buy |
| 5 | PHVS | Pharvaris N.V. | +1.7% | NEW | New buy |
| 6 | NTLA | Intellia Therapeutics Inc | +1% | NEW | New buy |
| 7 | ELVN | Enliven Therapeutics Inc | +0.9% | NEW | New buy |
| 8 | OCUL | Ocular Therapeutix Inc | +0.8% | NEW | New buy |
| 9 | CATBUSD | Astria Therapeutics Inc | +0.2% | NEW | New buy |
| 10 | ROIV | Roivant Sciences Ltd. | -7.6% | — | Unchanged |
| 11 | LQDA | Liquidia CORP | -13.4% | — | Unchanged |
According to official SEC Form 13F filings, Patient Square Capital LP reported a total U.S. public equity portfolio value of $645.5M across 11 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ROIV, LQDA, CGEM) accounted for 38.8% of total reported equity market value during Q3 2024.
Top New Position Initiated
CGEM
市值: $13.8M
During Q3 2024, Patient Square Capital LP's top holdings by market value included ROIV (52.4%)、LQDA (26.7%)、CGEM (5.1%). The largest single position, ROIV, represented 52.4% of total portfolio value.
In Q3 2024, Patient Square Capital LP made 9 total portfolio adjustments, initiating 9 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.